Product Name

  • Name

    Haloperidol

  • EINECS 200-155-6
  • CAS No. 52-86-8
  • Article Data29
  • CAS DataBase
  • Density 1.239 g/cm3
  • Solubility 2.058mg/L(22.5 oC)
  • Melting Point 152 °C
  • Formula C21H23ClFNO2
  • Boiling Point 529.034 °C at 760 mmHg
  • Molecular Weight 375.871
  • Flash Point 273.75 °C
  • Transport Information UN 2811 6.1/PG 3
  • Appearance white crystalline powder
  • Safety 53-26-36/37/39-45
  • Risk Codes 60-61-25-36/37/38-43
  • Molecular Structure Molecular Structure of 52-86-8 (Haloperidol)
  • Hazard Symbols ToxicT
  • Synonyms Butyrophenone,4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro- (6CI,8CI);4-(4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone;4-(4-Hydroxy-4'-chloro-4-phenylpiperidino)-4'-fluorobutyrophenone;Aloperidin;Bioperidolo;Brotopon;Dozic;Einalon S;Eukystol;Haldol;Haloperin;Keselan;McN-JR 1625;NSC 615296;Peluces;Serenace;Serenelfi;g-[4-(p-Chlorphenyl)-4-hydroxypiperidino]-p-fluorbutyrophenone;
  • PSA 40.54000
  • LogP 4.36350

Synthetic route

4-(4-chlorophenyl)-1-<4-(4-nitrophenyl)-4-oxobutyl>-4-piperidinol
150717-69-4

4-(4-chlorophenyl)-1-<4-(4-nitrophenyl)-4-oxobutyl>-4-piperidinol

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In dimethyl sulfoxide at 160℃; for 0.166667h; Inert atmosphere; Microwave irradiation; Anhydrous conditions;99%
With hydrogen fluoride; potassium oxalate; potassium carbonate; [2.2.2]cryptande65%
With hydrogen fluoride; potassium oxalate; potassium carbonate; [2.2.2]cryptande In dimethyl sulfoxide at 160℃; for 0.333333h;60%
4-(4-chlorophenyl)-4-hydroxypiperidine
39512-49-7

4-(4-chlorophenyl)-4-hydroxypiperidine

4-(4-fluorophenyl)-4-oxo-n-butyl chloride
3874-54-2

4-(4-fluorophenyl)-4-oxo-n-butyl chloride

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
With potassium carbonate; potassium iodide In acetonitrile at 75℃; for 24h; Temperature;88%
With potassium iodide In toluene for 45h; Reflux;85%
With potassium iodide In toluene at 130℃; for 45h; Sealed tube;79%
4-<4-(4-chlorophenyl)-4-hydroxypiperidino>-1,1-ethylenedioxy-1-(4-fluorophenyl)butane
56660-99-2

4-<4-(4-chlorophenyl)-4-hydroxypiperidino>-1,1-ethylenedioxy-1-(4-fluorophenyl)butane

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
With hydrogenchloride In methanol for 6h; Heating;65%
With hydrogenchloride In methanol for 2h; Heating;65%
4-fluorophenyl trifluoromethanesulfonate
132993-23-8

4-fluorophenyl trifluoromethanesulfonate

4-(4-chlorophenyl)-1-(4-hydroxybutyl)piperidin-4-ol

4-(4-chlorophenyl)-1-(4-hydroxybutyl)piperidin-4-ol

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
With 2,2,6,6-tetramethyl-piperidine; bis(1,5-cyclooctadiene)nickel (0); acetone; [2-((diphenylphospino)methyl)-2-methyl-1,3-propanediyl]bis[diphenylphosphine] In toluene at 130℃; for 20h; Inert atmosphere;37%
Chlorohaloperidol
59995-68-5

Chlorohaloperidol

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
With hydrogen fluoride; tetra(n-butyl)ammonium hydroxide
4-(4-chlorophenyl)-4-hydroxypiperidine
39512-49-7

4-(4-chlorophenyl)-4-hydroxypiperidine

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 78 percent / acetic acid; NaCNBH3 / methanol / 30 h / 20 °C
2: 65 percent / conc. HCl / methanol / 2 h / Heating
View Scheme
Multi-step reaction with 2 steps
1: K2CO3, KI / dimethylformamide / 17.5 h / 100 °C
2: 65 percent / conc. HCl / methanol / 6 h / Heating
View Scheme
Multi-step reaction with 2 steps
1: potassium iodide / toluene / 48 h / Reflux; Inert atmosphere
2: bis(1,5-cyclooctadiene)nickel (0); [2-((diphenylphospino)methyl)-2-methyl-1,3-propanediyl]bis[diphenylphosphine]; acetone; 2,2,6,6-tetramethyl-piperidine / toluene / 20 h / 130 °C / Inert atmosphere
View Scheme
methyl 3-(4-fluorobenzoyl)-propionate
39560-31-1

methyl 3-(4-fluorobenzoyl)-propionate

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 83 percent / p-TsOH / benzene / 20 h / Heating
2: 93 percent / DIBAL-H / CH2Cl2; tetrahydrofuran / 1 h / -78 °C
3: 78 percent / acetic acid; NaCNBH3 / methanol / 30 h / 20 °C
4: 65 percent / conc. HCl / methanol / 2 h / Heating
View Scheme
3-[2-(4-fluorophenyl)-[1,3]dioxolan-2-yl]propionaldehyde
847025-06-3

3-[2-(4-fluorophenyl)-[1,3]dioxolan-2-yl]propionaldehyde

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 78 percent / acetic acid; NaCNBH3 / methanol / 30 h / 20 °C
2: 65 percent / conc. HCl / methanol / 2 h / Heating
View Scheme
3-[2-(4-fluorophenyl)-[1,3]dioxolan-2-yl]propionic acid methyl ester
847025-05-2

3-[2-(4-fluorophenyl)-[1,3]dioxolan-2-yl]propionic acid methyl ester

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 93 percent / DIBAL-H / CH2Cl2; tetrahydrofuran / 1 h / -78 °C
2: 78 percent / acetic acid; NaCNBH3 / methanol / 30 h / 20 °C
3: 65 percent / conc. HCl / methanol / 2 h / Heating
View Scheme
(4-aminophenyl)(cyclopropyl)methanone
57189-90-9

(4-aminophenyl)(cyclopropyl)methanone

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 1) HBF4, NaNO2, 2) Cu, NaNO2 / 1) H2O, 30 min, 2) H2O, 1 h
2: 75 percent / conc. HCl / methanol / 0.5 h / 120 °C
3: 31 percent / KI / toluene / 100 - 110 °C
4: 60 percent / HF, potassium carbonate, potassium oxalate, kryptofix 222 / dimethylsulfoxide / 0.33 h / 160 °C
View Scheme
1-(4-acetylaminophenyl)-4-chloro-1-butanone
56924-11-9

1-(4-acetylaminophenyl)-4-chloro-1-butanone

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 90 percent / 4 M NaOH / ethanol / 2 h / Heating
2: 1) HBF4, NaNO2, 2) Cu, NaNO2 / 1) H2O, 30 min, 2) H2O, 1 h
3: 75 percent / conc. HCl / methanol / 0.5 h / 120 °C
4: 31 percent / KI / toluene / 100 - 110 °C
5: 60 percent / HF, potassium carbonate, potassium oxalate, kryptofix 222 / dimethylsulfoxide / 0.33 h / 160 °C
View Scheme
Acetanilid
103-84-4

Acetanilid

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 20 percent / AlCl3 / CS2 / room temperature, 30 min; 60 deg C, 2 h
2: 90 percent / 4 M NaOH / ethanol / 2 h / Heating
3: 1) HBF4, NaNO2, 2) Cu, NaNO2 / 1) H2O, 30 min, 2) H2O, 1 h
4: 75 percent / conc. HCl / methanol / 0.5 h / 120 °C
5: 31 percent / KI / toluene / 100 - 110 °C
6: 60 percent / HF, potassium carbonate, potassium oxalate, kryptofix 222 / dimethylsulfoxide / 0.33 h / 160 °C
View Scheme
cyclopropyl(4-nitrophenyl)methanone
93639-12-4

cyclopropyl(4-nitrophenyl)methanone

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 75 percent / conc. HCl / methanol / 0.5 h / 120 °C
2: 31 percent / KI / toluene / 100 - 110 °C
3: 60 percent / HF, potassium carbonate, potassium oxalate, kryptofix 222 / dimethylsulfoxide / 0.33 h / 160 °C
View Scheme
4-chloro-4'-nitrobutyrophenone
93639-13-5

4-chloro-4'-nitrobutyrophenone

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 31 percent / KI / toluene / 100 - 110 °C
2: 60 percent / HF, potassium carbonate, potassium oxalate, kryptofix 222 / dimethylsulfoxide / 0.33 h / 160 °C
View Scheme
4-(4-fluorophenyl)-4-oxo-n-butyl chloride
3874-54-2

4-(4-fluorophenyl)-4-oxo-n-butyl chloride

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: p-toluenesulfonic acid / benzene / 12 h / Heating
2: K2CO3, KI / dimethylformamide / 17.5 h / 100 °C
3: 65 percent / conc. HCl / methanol / 6 h / Heating
View Scheme
4-chloro-1-(4-fluorophenyl)-1,1-(ethylenedioxy)butane
3308-94-9

4-chloro-1-(4-fluorophenyl)-1,1-(ethylenedioxy)butane

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: K2CO3, KI / dimethylformamide / 17.5 h / 100 °C
2: 65 percent / conc. HCl / methanol / 6 h / Heating
View Scheme
fluorobenzene
462-06-6

fluorobenzene

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: AlCl3
2: toluene
View Scheme
4-Brom-4-(4-chlor-phenyl)-piperidin
91335-13-6

4-Brom-4-(4-chlor-phenyl)-piperidin

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: NaOH-solution; water
2: toluene
View Scheme
reduced haloperidol
34104-67-1

reduced haloperidol

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
With manganese dioxide In chloroform
1-(4-chlorobut-1-yn-1-yl)-4-fluorobenzene
1183278-95-6

1-(4-chlorobut-1-yn-1-yl)-4-fluorobenzene

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: iron(III) chloride; water; silver(I) triflimide / 1,4-dioxane / 18 h
2: potassium iodide / toluene / 25 h / 125 °C
View Scheme
Multi-step reaction with 2 steps
1: bis(trifluoromethanesulfonyl)amide; water / 1,4-dioxane / 100 °C
2: potassium iodide; sodium hydrogencarbonate / toluene / 100 °C
View Scheme
bromochlorobenzene
106-39-8

bromochlorobenzene

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: iodine; magnesium / tetrahydrofuran / 4 h / 60 - 70 °C / Inert atmosphere
1.2: 6 h / 30 °C / Inert atmosphere
1.3: 3 h / 60 °C / Inert atmosphere
2.1: hydrogen; palladium on activated charcoal / water / 24 h / 25 °C / 750.08 Torr
3.1: potassium carbonate; potassium iodide / acetonitrile / 24 h / 75 °C
View Scheme
N-benzyl-2-piperidinone
4783-65-7

N-benzyl-2-piperidinone

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: iodine; magnesium / tetrahydrofuran / 4 h / 60 - 70 °C / Inert atmosphere
1.2: 6 h / 30 °C / Inert atmosphere
1.3: 3 h / 60 °C / Inert atmosphere
2.1: hydrogen; palladium on activated charcoal / water / 24 h / 25 °C / 750.08 Torr
3.1: potassium carbonate; potassium iodide / acetonitrile / 24 h / 75 °C
View Scheme
N-benzyl-4-(4-chlorophenyl)-4-hydroxypiperidin
56108-25-9

N-benzyl-4-(4-chlorophenyl)-4-hydroxypiperidin

haloperidol
52-86-8

haloperidol

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: hydrogen; palladium on activated charcoal / water / 24 h / 25 °C / 750.08 Torr
2: potassium carbonate; potassium iodide / acetonitrile / 24 h / 75 °C
View Scheme
haloperidol
52-86-8

haloperidol

C21H21(2)H2ClFNO2

C21H21(2)H2ClFNO2

Conditions
ConditionsYield
With tris(pentafluorophenyl)borate; water-d2 In toluene at 100℃; for 12h; Inert atmosphere; regioselective reaction;97%
With [(N,N′-bis(2,6-diisopropylphenyl)-2,3-butanediimine)Ni(μ−H)]2; deuterium at -196 - 80℃; under 760.051 Torr; for 24h; Reagent/catalyst; Sealed tube;32 mg
haloperidol
52-86-8

haloperidol

benzoyl chloride
98-88-4

benzoyl chloride

benzoic acid haloperidol ester

benzoic acid haloperidol ester

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dichloromethane for 24h; Inert atmosphere;96.7%
haloperidol
52-86-8

haloperidol

Haloperidol N-oxide

Haloperidol N-oxide

Conditions
ConditionsYield
With perfluoro-cis-2-n-butyl-3-n-propyloxaziridine; HCFC-225ca,cb In dichloromethane at -60℃; for 0.333333h;96%
In CaH2; dichloromethane71%
haloperidol
52-86-8

haloperidol

4-[4-(4-deuteriophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone

4-[4-(4-deuteriophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone

Conditions
ConditionsYield
With bis(η3-allyl-μ-chloropalladium(II)); 1-deuteriodiphenylmethanol; 3-(2,6-dibenzhydryl-4-methylphenyl)-4,5-dimethyl-1-(2,4,6-trimethylbenzyl)imidazolium chloride; caesium carbonate In toluene at 90℃; for 16h; Inert atmosphere;94%
haloperidol
52-86-8

haloperidol

7,7',8,8'-tetracyanoquinodimethane
1518-16-7

7,7',8,8'-tetracyanoquinodimethane

C21H23ClFNO2*C12H4N4
1421948-04-0

C21H23ClFNO2*C12H4N4

Conditions
ConditionsYield
In methanol; chloroform at 20℃; for 0.75h;93%
haloperidol
52-86-8

haloperidol

cyclohexylamine
108-91-8

cyclohexylamine

4-<4-(4-Chlorophenyl)-4-hydroxypiperidino>-4'-(cyclohexylamino)butyrophenone

4-<4-(4-Chlorophenyl)-4-hydroxypiperidino>-4'-(cyclohexylamino)butyrophenone

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide for 5h; Heating;92%
haloperidol
52-86-8

haloperidol

N,N-dimethylethylenediamine
108-00-9

N,N-dimethylethylenediamine

4-<4-(4-Chlorophenyl)-4-hydroxypiperidino>-4'-<<2-(dimethylamino)ethyl>amino>butyrophenone

4-<4-(4-Chlorophenyl)-4-hydroxypiperidino>-4'-<<2-(dimethylamino)ethyl>amino>butyrophenone

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide for 5h; Heating;92%
2-(2-methylphenyl)pyridine
10273-89-9

2-(2-methylphenyl)pyridine

haloperidol
52-86-8

haloperidol

C33H33FN2O2

C33H33FN2O2

Conditions
ConditionsYield
With C17H24N5Ru(1+)*F6P(1-); potassium acetate; potassium carbonate In 1-methyl-pyrrolidin-2-one at 35℃; for 48h; Inert atmosphere;92%
haloperidol
52-86-8

haloperidol

3-trifluoromethylaniline
98-16-8

3-trifluoromethylaniline

1-(4-fluorophenyl)-4-(4-hydroxy-4-(4-((3-(trifluoromethyl)phenyl)amino)phenyl)piperidin-1-yl)butan-1-one
1612891-27-6

1-(4-fluorophenyl)-4-(4-hydroxy-4-(4-((3-(trifluoromethyl)phenyl)amino)phenyl)piperidin-1-yl)butan-1-one

Conditions
ConditionsYield
With Pd-PEPPSI-(2,6-(3-pentyl)pentylphenyl-2H-imidazol-2-ylidene)Cl-o-picoline; caesium carbonate In 1,2-dimethoxyethane at 45℃; for 24h; Buchwald-Hartwig Coupling; Inert atmosphere; Glovebox;91%
haloperidol
52-86-8

haloperidol

reduced haloperidol
34104-67-1

reduced haloperidol

Conditions
ConditionsYield
With sodium tetrahydroborate In methanol at 20℃; for 1.33333h;90%
With sodium tetrahydroborate In ethanol at 0 - 20℃;90%
With human liver dihydrodiol dehydrogenase 1; NADPH In phosphate buffer at 25℃; pH=6.0; Enzyme kinetics; Further Variations:; Reagents;
1,2-propanediene
463-49-0

1,2-propanediene

haloperidol
52-86-8

haloperidol

C24H29ClFNO2

C24H29ClFNO2

Conditions
ConditionsYield
Stage #1: haloperidol With copper diacetate; 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl In tetrahydrofuran for 0.0833333h; Inert atmosphere;
Stage #2: 1,2-propanediene With (dimethoxy)methylsilane In tetrahydrofuran at 20℃; for 12h; Inert atmosphere;		90%
piperidine
110-89-4

piperidine

haloperidol
52-86-8

haloperidol

4-<4-(4-Chlorophenyl)-4-hydroxypiperidino>-4'-piperidinobutyrophenone

4-<4-(4-Chlorophenyl)-4-hydroxypiperidino>-4'-piperidinobutyrophenone

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide for 3h; Ambient temperature;89%
haloperidol
52-86-8

haloperidol

2,4,6-Trinitrophenol
88-89-1

2,4,6-Trinitrophenol

C21H23ClFNO2*C6H3N3O7
1216665-74-5

C21H23ClFNO2*C6H3N3O7

Conditions
ConditionsYield
In methanol; chloroform at 20℃; for 0.75h;89%
haloperidol
52-86-8

haloperidol

C21H19(2)H4ClFNO2

C21H19(2)H4ClFNO2

Conditions
ConditionsYield
With [(N,N’-bis(1R,2R,3R,5S)-(−)-isopinocampheyl-1,2-ethanediimine-radical)NiI(μ2-H)]2; deuterium at -196 - 80℃; under 760.051 Torr; for 24h; Reagent/catalyst; Sealed tube;89%
1.3-propanedithiol
109-80-8

1.3-propanedithiol

haloperidol
52-86-8

haloperidol

(1,3-propanethioacetal)-4-[4-(p-chlorophenyl)-4-hydroxypiperidinyl]-4'-fluorobutyrophenone

(1,3-propanethioacetal)-4-[4-(p-chlorophenyl)-4-hydroxypiperidinyl]-4'-fluorobutyrophenone

Conditions
ConditionsYield
With trifluoroborane diethyl ether In methanol; hexane; dichloromethane; ethyl acetate88%
haloperidol
52-86-8

haloperidol

1-ethylpropylzinc bromide

1-ethylpropylzinc bromide

1-(4-fluorophenyl)-4-(4-hydroxy-4-(4-(pentan-3-yl)phenyl)piperidin-1-yl)butan-1-one

1-(4-fluorophenyl)-4-(4-hydroxy-4-(4-(pentan-3-yl)phenyl)piperidin-1-yl)butan-1-one

Conditions
ConditionsYield
Stage #1: haloperidol With C40H55Cl5N3Pd In toluene at 0℃; for 0.0833333h; Negishi Coupling; Inert atmosphere; Cooling with ice;
Stage #2: 1-ethylpropylzinc bromide In tetrahydrofuran; toluene at 23℃; for 16h; Inert atmosphere;		88%
haloperidol
52-86-8

haloperidol

propargyl bromide
106-96-7

propargyl bromide

C24H26ClFNO2(1+)*Br(1-)

C24H26ClFNO2(1+)*Br(1-)

Conditions
ConditionsYield
In tetrahydrofuran for 2h; Solvent; Temperature; Inert atmosphere; Reflux;88%
haloperidol
52-86-8

haloperidol

(+)-Dihydrohaloperidol

(+)-Dihydrohaloperidol

Conditions
ConditionsYield
With C37H40MnN2O2P2(1+)*Br(1-); sodium t-butanolate In isopropyl alcohol; toluene at 50℃; for 6h; Inert atmosphere; Schlenk technique; enantioselective reaction;85%
haloperidol
52-86-8

haloperidol

A

C42H47F2N3O4

C42H47F2N3O4

B

4-<4-hydroxy-4-(4-aminophenyl)piperidinyl>-1-(4-fluorophenyl)butanone
114361-10-3

4-<4-hydroxy-4-(4-aminophenyl)piperidinyl>-1-(4-fluorophenyl)butanone

Conditions
ConditionsYield
With C46H71Cl3N2Pd; ammonia; sodium t-butanolate In 1,4-dioxane at 80℃; for 2h; Inert atmosphere; Schlenk technique;A n/a
B 84%
haloperidol
52-86-8

haloperidol

4-(4-chlorophenyl)-1-<4-(4-fluorophenyl)-4-oxobutyl>-1,2,3,6-tetrahydopyridine
52669-92-8

4-(4-chlorophenyl)-1-<4-(4-fluorophenyl)-4-oxobutyl>-1,2,3,6-tetrahydopyridine

Conditions
ConditionsYield
With hydrogenchloride; acetic acid for 24h; Reflux; Inert atmosphere;84%
N-tert-butyldimethylsilyl-S-fluoromethyl-S-(2-pyridyl)sulfoximine

N-tert-butyldimethylsilyl-S-fluoromethyl-S-(2-pyridyl)sulfoximine

haloperidol
52-86-8

haloperidol

(E)-4-(4-chlorophenyl)-1-(5-fluoro-4-(4-fluorophenyl)pent-4-enyl)piperidin-4-ol

(E)-4-(4-chlorophenyl)-1-(5-fluoro-4-(4-fluorophenyl)pent-4-enyl)piperidin-4-ol

Conditions
ConditionsYield
Stage #1: N-tert-butyldimethylsilyl-S-fluoromethyl-S-(2-pyridyl)sulfoximine With potassium hexamethylsilazane In tetrahydrofuran at -78℃; for 0.5h; Inert atmosphere;
Stage #2: haloperidol In tetrahydrofuran at -78℃; for 3h; Inert atmosphere; stereoselective reaction;		82%
haloperidol
52-86-8

haloperidol

1-amino-3-(dimethylamino)propane
109-55-7

1-amino-3-(dimethylamino)propane

4-<4-(4-Chlorophenyl)-4-hydroxypiperidino>-4'-<<3-(dimethylamino)propyl>amino>butyrophenone

4-<4-(4-Chlorophenyl)-4-hydroxypiperidino>-4'-<<3-(dimethylamino)propyl>amino>butyrophenone

Conditions
ConditionsYield
With potassium carbonate In N,N-dimethyl-formamide for 3h; Heating;80%
haloperidol
52-86-8

haloperidol

2-(aminooxy)-N,N-diethylethanamine dihydrochloride
21894-85-9, 87272-47-7, 113437-87-9

2-(aminooxy)-N,N-diethylethanamine dihydrochloride

4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one O-(2-diethylamino-ethyl)-oxime

4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one O-(2-diethylamino-ethyl)-oxime

Conditions
ConditionsYield
With pyridine In ethanol for 32h; Heating;76.9%
haloperidol
52-86-8

haloperidol

butan-1-ol
71-36-3

butan-1-ol

1-(n-Butoxyphenyl)-4-<4-(4-chlorophenyl)-4-hydroxypiperidino>-n-butyl alcohol

1-(n-Butoxyphenyl)-4-<4-(4-chlorophenyl)-4-hydroxypiperidino>-n-butyl alcohol

Conditions
ConditionsYield
With sodium amide for 1h; Heating;75%
haloperidol
52-86-8

haloperidol

4-(4'-chlorophenyl)-1-(4'-(4-fluorophenyl)butyl)piperidin-4-ol
164668-08-0

4-(4'-chlorophenyl)-1-(4'-(4-fluorophenyl)butyl)piperidin-4-ol

Conditions
ConditionsYield
With [(C6H6)(PCy3)(CO)RuH]+*BF4−; hydrogen; phenol In 1,4-dioxane; isopropyl alcohol under 1520.1 Torr; for 12h; Inert atmosphere; Glovebox; Schlenk technique; chemoselective reaction;68%
haloperidol
52-86-8

haloperidol

O-(2-Pyrrolidin-1-yl-ethyl)-hydroxylamine; hydrochloride

O-(2-Pyrrolidin-1-yl-ethyl)-hydroxylamine; hydrochloride

4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one O-(2-pyrrolidin-1-yl-ethyl)-oxime

4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one O-(2-pyrrolidin-1-yl-ethyl)-oxime

Conditions
ConditionsYield
With pyridine In ethanol for 32h; Heating;67.7%
3-(tert-butyloxycarbonylamino)propionic acid
3303-84-2

3-(tert-butyloxycarbonylamino)propionic acid

haloperidol
52-86-8

haloperidol

C29H36ClFN2O5
853994-07-7

C29H36ClFN2O5

Conditions
ConditionsYield
Stage #1: 3-(tert-butyloxycarbonylamino)propionic acid; haloperidol With dmap In dichloromethane for 0.5h; Cooling with ice;
Stage #2: With dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 25h; Cooling with ice;		64.6%

Haloperidol Consensus Reports

EPA Genetic Toxicology Program.

Haloperidol Specification

The Haloperidol, with the CAS registry number 52-86-8 and EINECS registry number 200-155-6, has the systematic name of 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one. It is a kind of white crystalline powder, and belongs to the following product categories: Organics; Aromatics; Heterocycles; Intermediates & Fine Chemicals; Pharmaceuticals; Dopamine receptor; Dopamine. The molecular formula of this chemical is C21H23ClFNO2.

The physical properties of Haloperidol are as following: (1)ACD/LogP: 3.76; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 1.232; (4)ACD/LogD (pH 7.4): 2.931; (5)ACD/BCF (pH 5.5): 1.261; (6)ACD/BCF (pH 7.4): 63.047; (7)ACD/KOC (pH 5.5): 7.871; (8)ACD/KOC (pH 7.4): 393.605; (9)#H bond acceptors: 3; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 7; (12)Polar Surface Area: 40.54 Å2; (13)Index of Refraction: 1.581; (14)Molar Refractivity: 101.012 cm3; (15)Molar Volume: 303.279 cm3; (16)Polarizability: 40.044×10-24cm3; (17)Surface Tension: 47.906 dyne/cm; (18)Density: 1.239 g/cm3; (19)Flash Point: 273.75 °C; (20)Enthalpy of Vaporization: 84.63 kJ/mol; (21)Boiling Point: 529.034 °C at 760 mmHg; (22)Vapour Pressure: 0 mmHg at 25°C. 

Preparation of Haloperidol: It can be prepared by the condensation of 4-chlorophenyl-4-hydroxypiperidine with γ-chloro-p-Fluorophenyl methyl ethyl ketone. And the intermediate γ-chloro-fluoro-butanone can be prepared by fluorobenzene, γ-butyrolactone and thionyl chloride.

Uses of Haloperidol: It is an effective agent in treatment of symptoms associated with schizophrenia, and it is also used in the control of the symptoms of: (1)Acute psychosis; (2)Acute manic phases until the concomitantly given first-line drugs; (3)Otherwise uncontrollable severe behavioral disorders in children and adolescents; (4)Agitation and confusion associated with cerebral sclerosis; (5)Adjunctive treatment of alcohol and opioid withdrawal; (6)Treatment of nausea, vomiting, and delirium in palliative care; (7)Treatment of neurological disorders such as tic disorders; (8)Tourette syndrome, and chorea; (9)Treatment of severe nausea/emesi; (10)Adjunctive treatment of severe chronic pain, always together with analgesics; (11)Therapeutic trial in personality disorders; (12)Also used in the treatment of intractable hiccups.

You should be cautious while dealing with this chemical. It irritates eyes, respiratory system and skin, and it is also toxic if swallowed. And it may cause sensitization by skin contact. What's more, it may impair fertility and harm to the unborn child. Therefore, you had better take the following instructions: Wear suitable protective clothing, gloves and eye/face protection, and in case of contacting with eyes, rinse immediately with plenty of water and seek medical advice; In case of accident or if you feel unwell, seek medical advice immediately (show label where possible); Avoid exposure - obtain special instruction before use.

You can still convert the following datas into molecular structure:
(1)SMILES: c1cc(ccc1C(=O)CCCN2CCC(CC2)(c3ccc(cc3)Cl)O)F
(2)InChI: InChI=1/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
(3)InChIKey: LNEPOXFFQSENCJ-UHFFFAOYAL

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LD50 subcutaneous > 2500ug/kg (2.5mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961.
child TDLo oral 72ug/kg (0.072mg/kg) BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) American Journal of Psychiatry. Vol. 143, Pg. 1176, 1985.
child TDLo unreported 375ug/kg/3D (0.375mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)		 Lancet. Vol. 2, Pg. 479, 1980.
dog LD50 intravenous 18mg/kg (18mg/kg)   Clinical Pharmacology and Therapeutics Vol. 8, Pg. 770, 1967.
dog LD50 oral 90mg/kg (90mg/kg)   Clinical Pharmacology and Therapeutics Vol. 8, Pg. 770, 1967.
dog LD50 subcutaneous > 80mg/kg (80mg/kg)   Clinical Pharmacology and Therapeutics Vol. 8, Pg. 770, 1967.
human TDLo oral 71ug/kg (0.071mg/kg) BEHAVIORAL: EXCITEMENT Journal of Clinical Pyschopharmacology. Vol. 5, Pg. 120, 1985.
human TDLo unreported 9800ug/kg/28D (9.8mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: TREMOR

BEHAVIORAL: ATAXIA		 Arzneimittel-Forschung. Drug Research. Vol. 32, Pg. 911, 1982.
infant TDLo unreported 280ug/kg (0.28mg/kg) BEHAVIORAL: EXCITEMENT

BEHAVIORAL: AGGRESSION

BEHAVIORAL: IRRITABILITY		 Acta Paediatrica. Vol. 82, Pg. 877, 1993.
mammal (species unspecified) LD50 oral 80mg/kg (80mg/kg)   Doklady Akademii Nauk SSSR. Proceedings of the Academy of Sciences of the USSR. For English translation, see DBIOAM and DKBSAS. Vol. 320, Pg. 242, 1991.
mammal (species unspecified) LD50 unreported 80mg/kg (80mg/kg)   Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 24(7), Pg. 27, 1990.
man TDLo multiple routes 343ug/kg (0.343mg/kg) BEHAVIORAL: TREMOR Southern Medical Journal. Vol. 76, Pg. 546, 1983.
man TDLo multiple routes 1mg/kg/1D-I (1mg/kg) BEHAVIORAL: MUSCLE WEAKNESS Journal of Clinical Pyschopharmacology. Vol. 3, Pg. 338, 1983.
man TDLo oral 480ug/kg/6D-I (0.48mg/kg) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

BEHAVIORAL: EXCITEMENT

BEHAVIORAL: REGIDITY		 American Journal of Psychiatry. Vol. 142, Pg. 389, 1985.
man TDLo oral 9mg/kg/30W-I (9mg/kg) PERIPHERAL NERVE AND SENSATION: FASCICULATIONS Biological Psychiatry. Vol. 22, Pg. 111, 1987.
man TDLo unreported 500ug/kg/5D-I (0.5mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) JAMA, Journal of the American Medical Association. Vol. 250, Pg. 485, 1983.
monkey LD50 subcutaneous > 1250ug/kg (1.25mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961.
mouse LD50 intraperitoneal 30mg/kg (30mg/kg)   Bollettino Chimico Farmaceutico. Vol. 111, Pg. 293, 1972.
mouse LD50 intravenous 13mg/kg (13mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: REGIDITY		 Arzneimittel-Forschung. Drug Research. Vol. 11, Pg. 932, 1961.
mouse LD50 oral 71mg/kg (71mg/kg)   Farmaco, Edizione Scientifica. Vol. 31, Pg. 442, 1976.
mouse LD50 subcutaneous 41mg/kg (41mg/kg)   Oyo Yakuri. Pharmacometrics. Vol. 1, Pg. 74, 1967.
mouse LD50 unreported 18mg/kg (18mg/kg)   Clinical Pharmacology and Therapeutics Vol. 3, Pg. 432, 1962.
rabbit LD50 intravenous 8mg/kg (8mg/kg)   Clinical Pharmacology and Therapeutics Vol. 8, Pg. 770, 1967.
rat LD50 intraperitoneal 27mg/kg (27mg/kg)   "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 190, 1972.
rat LD50 intravenous 15mg/kg (15mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 24, Pg. 45, 1974.
rat LD50 oral 128mg/kg (128mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 24, Pg. 45, 1974.
rat LD50 subcutaneous 60mg/kg (60mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 24, Pg. 45, 1974.
women TDLo intravenous 18300ug/kg/7D (18.3mg/kg) CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)

CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE		 Annals of Pharmacotherpy. Vol. 33, Pg. 1046, 1999.
women TDLo oral 100ug/kg/10D- (0.1mg/kg) BLOOD: AGRANULOCYTOSIS Journal of the American Geriatrics Society. Vol. 35, Pg. 248, 1987.

Related Products

Hot Products

Post buying leads

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View